GlassScriptPhysician profile
Karie L Fedorick
NPI 1689735482
$4,690.64
in general payments reported to CMS, 2019-2025
37 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $1,078 · 2023: $663 · 2024: $1,271 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $909.85 | 2022 | |
| Abbvie INC. | $892.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $658.83 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $457.72 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $249.89 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $192.25 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $124.01 | 2023-2025 | |
| Amgen INC. | $121.77 | 2023-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $96.07 | 2024-2025 | Veozah |
| Aimmune Therapeutics, INC. | $87.67 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $76.50 | 2023-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.46 | 2023-2025 | Xifaxan |
| Lucid Diagnostics INC. | $62.93 | 2021 | |
| Sanofi Pasteur INC. | $60.45 | 2023 | |
| Axonics, INC. | $49.89 | 2023-2024 | Axonics |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $47.93 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $43.88 | 2024 | Teriparatide, Loreev Xr |
| Currax Pharmaceuticals LLC | $43.80 | 2022-2024 | Contrave |
| Dexcom, INC. | $41.77 | 2025 | Dexcom G6 Transmitter |
| Nalu Medical, INC. | $41.36 | 2023-2024 | Nalu Neurostimulation System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.80 | 2025 | Caplyta |
| Shield Therapeutics INC | $38.87 | 2023-2025 | Accrufer |
| Harmony Biosciences LLC | $28.39 | 2024 | |
| Renalytix Ai, INC. | $23.98 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Nevro Corp. | $21.67 | 2021 | |
| Acella Pharmaceuticals, LLC | $19.75 | 2024 | NP Thyroid 60 |
| Boston Scientific Corporation | $19.30 | 2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.26 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $18.74 | 2025 | Capvaxive, Gardasil 9 |
| Phadia US INC. | $18.47 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.37 | 2022 | |
| Exact Sciences Corporation | $17.88 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $17.50 | 2025 | |
| Glaxosmithkline, LLC. | $17.10 | 2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.31 | 2024 | Quviviq |
| Insulet Corporation | $14.34 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karie Fedorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.